Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc1.4 | Neuroendocrinology and pituitary | ECE2008

Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a phase II extension study

Farrall Andrew J , Glusman Joan E , Ruffin Matthieu , Petersenn Stephan

Introduction: In a recent 16-week Phase II study in patients with de novo, persistent or recurrent acromegaly, pasireotide effectively controlled GH and/or IGF-I levels in 56% of patients, and reduced tumor volume by >20% in 39% of patients. We present preliminary 6-month results from the ongoing extension phase of this study.Methods: This extension study enrolled patients who achieved biochemical control (GH ≤2.5 μg/l and normalize...